Market Overview

Goldman Sachs Upgrades Onyx Pharmaceuticals to CL-Buy


Goldman Sachs has upgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Buy to CL-Buy and has added the company to its Americas Conviction List. Price target has been raised from $45 to $47.

Posted-In: Americas Conviction Buy List Goldman SachsUpgrades Price Target Pre-Market Outlook Analyst Ratings


Related Articles (ONXX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→